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decreased while PGA increased. A 1998–2003 linear extrapo-
lated market share would have predicted a crossing of the two
curves around 2005, reinforced by the new 1st line indication of
PGA authorized by the EMEA in 2002. This did not occur which
might be explained by the non-reimbursement of PGA for ﬁrst
line therapy in Italy. Accordingly, yearly Padova area drug spend-
ing was €150,000 less than predicted, on a €600,000 yearly
budget. The comparison of IMS data shows two countries where
the BB are still prescribed more than PGA, Italy and Germany.
The latter is a country where physicians’ fees are reduced if their
glaucoma prescription costs exceed their government set budget.
PGA monotherapy treatment persistence was longer than with
BB, according to Padova and UK GPRD data, in PGA-naive
patients. This holds true for ﬁrst line and second line treatment
(UK GPRD); the persistency of a second line PGA equaled ﬁrst
line BB treatment. A short treatment persistency is known to be
associated with high cost and disease progression. CONCLU-
SIONS: Health care regulation impacted glaucoma prescribing
and might be one of the reasons for differences observed between
the ﬁve European countries. Evaluations of both the cost conse-
quences beyond the drug budget and the public health impact
should always accompany the establishment of health care
regulations.
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OBJECTIVES: This analysis evaluated whether the Dermatology
Life Quality Index (DLQI) and the Psoriasis Area and Severity
Index (PASI) have different responsiveness to measure change
of treatment effect in moderate to severe psoriasis patients.
METHODS: In PHOENIX I, 766 patients were randomized to
ustekinumab 45 mg or 90 mg at weeks 0 and 4 and then q12
weeks thereafter, or placebo at weeks 0 and 4 with crossover
to ustekinumab at week 12. Ustekinumab-randomized patients
achieving PASI75 response at weeks 28 and 40 were re-
randomized at week 40 to continue maintenance ustekinumab or
be withdrawn from treatment until loss of response. DLQI and
PASI were assessed at weeks 0, 2, 12, 28, 40 and 52. Multiple
regression models were used to assess treatment effect on DLQI
by adjusting for PASI improvement. RESULTS: Signiﬁcantly
greater proportions of patients receiving ustekinumab achieved
PASI75 response (66.7%) and clinically meaningful improve-
ment (5 points) in DLQI (67.8%) compared with placebo
(3.1% and 6.0%, each p < 0.001) at week 12. There was a
signiﬁcant correlation between the change in DLQI and change
in PASI (r = 0.65, p < 0.001). After adjustment for baseline
DLQI, baseline PASI, and change in PASI, ustekinumab was still
associated with signiﬁcant improvement in DLQI (p < 0.001).
For patients originally randomized to ustekinumab, the median
% improvement from baseline was higher in DLQI (37.5%) than
in PASI (21.4%) at week 2, with 11.4% of patients achieving a
DLQI score of 1, but only 1% achieving a PASI75 response. At
week 28 and 40, the DLQI and PASI achieved and maintained
similar improvements of 90% from baseline. For those who
achieved and maintained a PASI75 response from week 12
through week 40, but lost response at week 52, the median
improvement in DLQI decreased more signiﬁcantly (100% at
week 40 to 46% at week 52, a 54% reduction) than PASI that
decreased from 88.9% at week 40 to 57.6% at week 52 (35.0%
reduction). CONCLUSIONS: The DLQI may be more respon-
sive to change of disease status due to treatment intervention
than PASI.
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OBJECTIVES: The primary treatment for minor to moderate
bleeding disorders in haemophilia patients with inhibitors is
either rFVIIa or aPCC. The efﬁcacy of both products has been
evaluated in individual studies; however there has not been an
overall review and attempt to establish a valid estimate of the
effectiveness of rFVIIa and aPCC. We undertook a systematic
review of the literature in an attempt to establish robust estimates
of the efﬁcacy, speed of bleed resolution, and adverse event
proﬁle of both rFVIIa and aPCC. METHODS: We identiﬁed 11
open-label cohort studies, six randomized clinical trials, includ-
ing two head-to-head clinical trials and a meta-analysis. The
deﬁnition of efﬁcacy varies between these studies, but is usually a
composite measure of deﬁnite relief of pain, reduction in the size
of the haemorrhage, and cessation of bleeding. The individual
making the interpretation of efﬁcacy (i.e., the clinician, the
patient/caregiver, or a combination of both) and the time from
treatment initiation to the recording of the efﬁcacy endpoint also
varies across the studies. RESULTS: Overall, estimates of efﬁcacy
based on randomized clinical trials using dosing regimens in line
with guidelines are higher for rFVIIa (81%–91%) than for aPCC
(64–80%). Conclusions from a meta-analysis suggest that treat-
ment with rFVIIa may be associated with a faster time to joint
bleed resolution than aPCC due to higher efﬁcacy levels at 12, 24
and 36 hour time points. The results from a comparative trial
support the improved efﬁcacy rates associated with rFVIIa com-
pared to aPCC. CONCLUSIONS: In general, the studies do
report higher efﬁcacy and bleed cessation rates for rFVIIa than
for aPCC; however, the measurement of effectiveness of the
agents is open to interpretation due to variety of methods being
used to evaluate effectiveness. Further head-to-head trials should
incorporate a standardized measurement for deﬁning efﬁcacy.
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OBJECTIVES: To review how the Fabry Outcome Survey (FOS),
a physician-driven multinational database supported by Shire
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